B. Riley Comments on GENFIT S A/ADR’s Q1 2019 Earnings (NASDAQ:GNFT)

GENFIT S A/ADR (NASDAQ:GNFT) – Analysts at B. Riley lowered their Q1 2019 earnings estimates for GENFIT S A/ADR in a report released on Wednesday, June 12th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.78) per share for the quarter, down from their prior forecast of ($0.73). B. Riley also issued estimates for GENFIT S A/ADR’s Q2 2019 earnings at ($0.89) EPS, Q3 2019 earnings at ($0.70) EPS, Q4 2019 earnings at ($0.98) EPS, FY2019 earnings at ($3.37) EPS, FY2020 earnings at ($3.90) EPS, FY2021 earnings at ($3.36) EPS, FY2022 earnings at $0.07 EPS and FY2023 earnings at $0.46 EPS.

Several other analysts also recently weighed in on GNFT. Barclays began coverage on shares of GENFIT S A/ADR in a report on Monday, April 22nd. They issued an “overweight” rating and a $55.00 target price on the stock. Svb Leerink began coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an “outperform” rating and a $58.00 target price on the stock. Leerink Swann began coverage on shares of GENFIT S A/ADR in a report on Wednesday, April 24th. They issued an “outperform” rating and a $25.47 target price on the stock. Roth Capital reaffirmed a “buy” rating on shares of GENFIT S A/ADR in a report on Tuesday, April 23rd. Finally, HC Wainwright reduced their price objective on shares of GENFIT S A/ADR to $72.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Five analysts have rated the stock with a buy rating, GENFIT S A/ADR presently has an average rating of “Buy” and a consensus price target of $52.62.

Shares of GENFIT S A/ADR stock opened at $21.53 on Friday. GENFIT S A/ADR has a 1 year low of $20.12 and a 1 year high of $26.25.

A number of institutional investors and hedge funds have recently made changes to their positions in GNFT. Morgan Stanley acquired a new position in GENFIT S A/ADR during the first quarter worth about $206,000. BlueCrest Capital Management Ltd acquired a new position in GENFIT S A/ADR during the first quarter worth about $240,000. New York State Common Retirement Fund acquired a new position in GENFIT S A/ADR during the first quarter worth about $267,000. One68 Global Capital LLC acquired a new position in GENFIT S A/ADR during the first quarter worth about $270,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in GENFIT S A/ADR during the first quarter worth about $449,000. Institutional investors own 15.31% of the company’s stock.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Read More: Intrinsic Value and Stock Selection

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.